Literature DB >> 8231787

Meningococcal disease in patients with late complement component deficiency: studies in the U.S.S.R.

A E Platonov1, V B Beloborodov, I V Vershinina.   

Abstract

The purpose of this study was to examine the occurrence of late complement component deficiency (LCCD) states in the USSR. Thirty deficient individuals were detected: 27 with C8 beta and 3 with C7 deficiency. Among individuals with a first episode of meningococcal infection, about 1% had LCCD, whereas among patients with recurrent bacterial meningitis the prevalence of LCCD rose to approximately 50%. This corresponds to a prevalence for LCCD of approximately 12 per 100,000 in the general population. The individuals with LCCD identified in this study experienced about 77 episodes of meningococcal disease and acute bacterial meningitis. Mathematical analysis of the morbidity from meningococcal disease in individuals with LCCD demonstrated that the probability of disease did not change with the age of the patient and was not affected by prior episodes of infection. This finding suggest that in contrast to the situation in the general population, prior infection fails to protect the deficient individual from recurrent disease. In comparison to complement-sufficient persons, the course of disease in individuals with LCCD is less severe, as shown by a reduction in the number of episodes of endotoxic shock and mortality as well as their more rapid recovery. These findings suggest that exuberant complement activation and concomitant formation of membrane attack complexes during meningococcal infection in complement-sufficient patients plays an important role in the activation and injury of peripheral blood cells and endothelial cells during endotoxic shock.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8231787     DOI: 10.1097/00005792-199311000-00002

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  23 in total

Review 1.  Molecular mechanisms of complement component C6 deficiency; a hypervariable exon 6 region responsible for three of six reported defects.

Authors:  A Orren
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

Review 2.  Complement deficiency.

Authors:  K M O'Neil
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

Review 3.  Clinical implications of the specialised B cell response to polysaccharide encapsulated pathogens.

Authors:  C G Vinuesa; C de Lucas; M C Cook
Journal:  Postgrad Med J       Date:  2001-09       Impact factor: 2.401

Review 4.  The immunopathogenesis of meningococcal disease.

Authors:  A J Kvalsvig; D J Unsworth
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

5.  Development of antibodies against tetravalent meningococcal polysaccharides in revaccinated complement-deficient patients.

Authors:  M Drogari-Apiranthitou; C A Fijen; D Van De Beek; E F Hensen; J Dankert; E J Kuijper
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

6.  High prevalence of complement component C6 deficiency among African-Americans in the south-eastern USA.

Authors:  Z Zhu; T P Atkinson; K T Hovanky; S B Boppana; Y L Dai; P Densen; R C Go; J S Jablecki; J E Volanakis
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

Review 7.  Epidemiology, etiology, pathogenesis, and diagnosis of recurrent bacterial meningitis.

Authors:  Marc Tebruegge; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 8.  Vaccination against meningococcus in complement-deficient individuals.

Authors:  B P Morgan; A Orren
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

9.  Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B.

Authors:  J S Plested; D M Granoff
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

10.  Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine.

Authors:  A E Platonov; V B Beloborodov; L I Pavlova; I V Vershinina; H Käyhty
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.